<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03672851</url>
  </required_header>
  <id_info>
    <org_study_id>anti-CD123 CAR-T therapy</org_study_id>
    <nct_id>NCT03672851</nct_id>
  </id_info>
  <brief_title>Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia</brief_title>
  <official_title>Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital of Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanjing Legend Biotech Co.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital of Xi'an Jiaotong University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open-label, phase 1 study, to determine the safety and efficacy of&#xD;
      anti-CD123 CAR-T cells in treating patients diagnosed with refractory/relapsed acute leukemia&#xD;
      in a dose-escalation way.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a dose-escalation study of autologous anti-CD123 CAR-T cells. Patients receive&#xD;
      fludarabine phosphate(300 mg/m^2) and cyclophosphamide (30 mg/m^2) IV on days -5 to -3, and&#xD;
      then Patients receive autologous anti-CD123 CAR T cells IV over 20 minutes on day 0 (20% of&#xD;
      total dose), day2 (30% of total dose) and day6 (50% of total dose, according to the&#xD;
      side-effects occured). The total dose of CAR-T cells used in dose-escalation study is&#xD;
      0.5x10^6- 2.0x10^6 CAR-T cells/kg.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    adverse effect&#xD;
  </why_stopped>
  <start_date type="Actual">April 17, 2019</start_date>
  <completion_date type="Actual">July 31, 2019</completion_date>
  <primary_completion_date type="Actual">July 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT)</measure>
    <time_frame>28 days</time_frame>
    <description>assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Day 1-60 months after injection</time_frame>
    <description>assessed by NCI CTCAE version 4.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease response (CR or CRi)</measure>
    <time_frame>Day 1-60 months after injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Day 1-60 months after injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease</measure>
    <time_frame>Day 1-60 months after injection</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Acute Leukemia</condition>
  <condition>Acute Leukemia in Relapse</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Relapsed or Refractory Acute Leukemia</condition>
  <arm_group>
    <arm_group_label>anti-CD123 CAR-T treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-CD123 CAR-T treatment</intervention_name>
    <description>Patients receive fludarabine phosphate(300 mg/m^2) and cyclophosphamide (30 mg/m^2) IV on days -5 to -3, and then Patients receive autologous anti-CD123 CAR T cells IV over 20 minutes on day 0 (20% of total dose), day2 (30% of total dose) and day6 (50% of total dose, according to the side-effects occured). The total dose of CAR-T cells used in dose-escalation study is 0.5x10^6- 2.0x10^6 CAR-T cells/kg.</description>
    <arm_group_label>anti-CD123 CAR-T treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Research patients enrolled are those patients with relapsed or refractory CD123+ acute&#xD;
             leukemia (Acute Myeloid Leukemia/ acute lymphoblastic leukemia );&#xD;
&#xD;
          2. Relapsed: is defined as patients that had a first complete remission (CR) before&#xD;
             developing recurrent disease (increased bone marrow blasts);&#xD;
&#xD;
          3. Refractory: is defined as patients that have not achieved a first CR after 2 cycles of&#xD;
             induction chemotherapy; for patients with leukemia evolving from myelodysplastic&#xD;
             syndrome, they should have completed at least one cycle of induction chemotherapy;&#xD;
&#xD;
          4. Research participants must have bone marrow and/or peripheral blood samples available&#xD;
             for confirmation of diagnosis; CD123 positivity must be confirmed by either flow&#xD;
             cytometry or immunohistochemistry within 90 days of study entry; cytogenetics, flow&#xD;
             cytometry, and molecular studies (such as FMS-like tyrosine kinase-3 [FLT-3] status)&#xD;
             will be obtained as per standard practice;&#xD;
&#xD;
          5. Karnofsky performance status score &gt;= 70;&#xD;
&#xD;
          6. Women of child-bearing potential and men must agree to use adequate contraception&#xD;
             prior to study entry and for six months following duration of study participation;&#xD;
             should a woman become pregnant or suspect that she is pregnant while participating on&#xD;
             the trial, she should inform her treating physician immediately;&#xD;
&#xD;
          7. Calculated creatinine clearance (absolute value) of &gt;= 50 mL/minute or creatinine &lt;&#xD;
             2.0 mg/dl or &lt; 2 times upper limit of normal for the research participant's age group;&#xD;
&#xD;
          8. Serum bilirubin =&lt; 3.0 mg/dL;&#xD;
&#xD;
          9. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =&lt; 5 times the&#xD;
             institutional upper limits of normal;&#xD;
&#xD;
         10. Ejection fraction measured by echocardiogram (ECHO) or multi gated acquisition scan&#xD;
             (MUGA) &gt;= 50%;&#xD;
&#xD;
         11. Diffusion capacity of carbon monoxide (DLCO) or forced expiratory volume in one second&#xD;
             (FEV1) &gt; 45% predicted;&#xD;
&#xD;
         12. Research participants' last dose of prior chemotherapy or radiation must be &gt;= 2 weeks&#xD;
             before leukapheresis;&#xD;
&#xD;
         13. If a research participant has undergone prior allogeneic stem cell transplant, he/she&#xD;
             must be off all immunosuppressants for graft versus host disease (GVHD) for at least 2&#xD;
             weeks before undergoing leukapheresis;&#xD;
&#xD;
         14. Negative serum or urine pregnancy test;&#xD;
&#xD;
         15. All research participants must have the ability to understand and willingness to sign&#xD;
             a written informed consent or age appropriate assent for pediatric patients.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute Promyelocytic Leukemia, t(15,17) (q22;q12);&#xD;
&#xD;
          2. Pregnant and lactating women;&#xD;
&#xD;
          3. Research participants who have tested human immunodeficiency virus (HIV) positive, or&#xD;
             have active hepatitis B or C infection, or poorly controlled infection;&#xD;
&#xD;
          4. History of allergic reactions attributed to compounds of similar chemical or&#xD;
             biological composition to cetuximab&#xD;
&#xD;
          5. Dependence on corticosteroids (5mg/day prednisone more than 2 weeks);&#xD;
&#xD;
          6. A known hypersensitivity to any of the test materials or related compounds;&#xD;
&#xD;
          7. Presence of active and clinically relevant Central Nervous System (CNS) disorder;&#xD;
&#xD;
          8. Undergone prior allogeneic stem cell transplant, GVHD occurred within 6 months,&#xD;
             requiring immunosuppressive therapy;&#xD;
&#xD;
          9. Active autoimmune disease, such as psoriasis and rheumatoid arthritis;&#xD;
&#xD;
         10. Other situations the clinicians think not eligible for participation in the research.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ai-Li He, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital of Xi'an Jiaotong University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>September 13, 2018</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2018</study_first_posted>
  <last_update_submitted>September 3, 2019</last_update_submitted>
  <last_update_submitted_qc>September 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

